Matching articles for "eye"
Issue 1759 · July 20, 2026
Omidenepag Isopropyl (Omlonti) for Glaucoma

The FDA has approved Omlonti (Ocuvex), a 0.002% ophthalmic solution of the prostaglandin EP 2 receptor agonist omidenepag isopropyl, for reduction of intraocular pressure (IOP) in patients with open-angle…

Med Lett Drugs Ther. 2026 Jul 20; 68(1759):114-6 doi:10.58347/tml.2026.1759b
The FDA has approved Omlonti (Ocuvex), a 0.002% ophthalmic solution of the prostaglandin EP 2 receptor agonist omidenepag isopropyl, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Omidenepag is the first selective prostaglandin EP 2 receptor agonist to be approved in the US. It has been available in Japan since 2018.
Issue 1755 · May 25, 2026
Yuvezzi — A Carbachol/Brimonidine Solution for Presbyopia

The FDA has approved Yuvezzi (Tenpoint), an ophthalmic solution containing the cholinergic agonist carbachol 2.75% and the alpha-adrenergic receptor agonist brimonidine 0.1%, for treatment of presbyopia.…

Med Lett Drugs Ther. 2026 May 25; 68(1755):84-5 doi:10.58347/tml.2026.1755b
The FDA has approved Yuvezzi (Tenpoint), an ophthalmic solution containing the cholinergic agonist carbachol 2.75% and the alpha-adrenergic receptor agonist brimonidine 0.1%, for treatment of presbyopia. Carbachol and brimonidine have been available in single-ingredient ophthalmic solutions for other indications for years.
Issue 1751 · March 30, 2026 Free
In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion

Eylea HD (Regeneron), which contains 8 mg of the vascular endothelial growth factor (VEGF) inhibitor aflibercept, has now been approved by the FDA for intravitreal treatment of macular edema following retinal…

Med Lett Drugs Ther. 2026 Mar 30; 68(1751):56 doi:10.58347/tml.2026.1751b
Eylea HD (Regeneron), which contains 8 mg of the vascular endothelial growth factor (VEGF) inhibitor aflibercept, has now been approved by the FDA for intravitreal treatment of macular edema following retinal vein occlusion (RVO). A 2-mg dose of aflibercept (Eylea) was approved previously for this indication. Eylea and Eylea HD are also approved for treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
Issue 1737 · September 15, 2025
Acoltremon (Tryptyr) for Dry Eye Disease

The FDA has approved acoltremon 0.003% ophthalmic solution ( Tryptyr – Alcon) for treatment of dry eye disease. Acoltremon is the first transient receptor potential melastatin 8 (TRPM8) thermoreceptor…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):145-6 doi:10.58347/tml.2025.1737a
The FDA has approved acoltremon 0.003% ophthalmic solution ( Tryptyr – Alcon) for treatment of dry eye disease. Acoltremon is the first transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist to be approved in the US for this indication.
Issue 1727 · April 28, 2025
Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia (online only)

Revakinagene taroretcel-lwey ( Encelto – Neurotech), an intravitreal allogeneic cell-based gene therapy, has been approved by the FDA for treatment of idiopathic macular telangiectasia type 2 in adults. It…

Med Lett Drugs Ther. 2025 Apr 28; 67(1727):e74 doi:10.58347/tml.2025.1727f
Revakinagene taroretcel-lwey ( Encelto – Neurotech), an intravitreal allogeneic cell-based gene therapy, has been approved by the FDA for treatment of idiopathic macular telangiectasia type 2 in adults. It is the first treatment to be approved in the US for this indication.
Issue 1723 · March 3, 2025
Drugs for Dry Eye Disease

Disruption of tear-film homeostasis (altered composition, reduced production, rapid evaporation) and resulting ocular surface inflammation cause the discomfort and blurred vision of dry eye disease. Many cases…

Med Lett Drugs Ther. 2025 Mar 3; 67(1723):35-7 doi:10.58347/tml.2025.1723b
Disruption of tear-film homeostasis (altered composition, reduced production, rapid evaporation) and resulting ocular surface inflammation cause the discomfort and blurred vision of dry eye disease. Many cases are caused by tear evaporation due to meibomian gland dysfunction. Other precipitating factors can include lacrimal gland dysfunction, poor eyelid function, environmental factors, extended screen time, inflammatory conditions such as Sjögren's syndrome, and use of some ocular or systemic drugs such as antihistamines, retinoids, or selective serotonin reuptake inhibitors (SSRIs). Benzalkonium chloride, a preservative used in some eye drops, can cause eye irritation and exacerbate symptoms of dry eye disease; use of preservative-free ophthalmic preparations is preferred. Dry eye disease is most prevalent in females and older adults, but its incidence in young people is increasing, possibly because of increased screen time.
Issue 1701 · April 29, 2024
iDose TR — A Travoprost Implant for Glaucoma

The FDA has approved iDose TR (Glaukos), an intracameral implant containing the prostaglandin analog (PGA) travoprost, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular…

Med Lett Drugs Ther. 2024 Apr 29; 66(1701):70-1 doi:10.58347/tml.2024.1701d
The FDA has approved iDose TR (Glaukos), an intracameral implant containing the prostaglandin analog (PGA) travoprost, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Travoprost is also available as a topical ophthalmic solution ( Travatan Z , and generics) for the same indication. iDose TR is the second ocular implant to become available in the US for this indication; Durysta , an intracameral implant containing the prostaglandin analog bimatoprost, was the first.
Issue 1694 · January 22, 2024
Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease

The FDA has approved perfluorohexyloctane ophthalmic solution ( Miebo – Bausch+Lomb) for treatment of dry eye disease. Available only by prescription, Miebo is the first ophthalmic product to be approved in…

Med Lett Drugs Ther. 2024 Jan 22; 66(1694):13-4 doi:10.58347/tml.2024.1694c
The FDA has approved perfluorohexyloctane ophthalmic solution ( Miebo – Bausch+Lomb) for treatment of dry eye disease. Available only by prescription, Miebo is the first ophthalmic product to be approved in the US that specifically targets tear evaporation caused by meibomian gland dysfunction. An ophthalmic solution with a similar name, Meibo Tears (Vista), which contains 0.6% propylene glycol, is available over the counter for dry eye relief.
Issue 1694 · January 22, 2024
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration

The FDA has approved the complement C5 inhibitor avacincaptad pegol ( Izervay – Iveric) for intravitreal treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Avacincaptad…

Med Lett Drugs Ther. 2024 Jan 22; 66(1694):15-6 doi:10.58347/tml.2024.1694d
The FDA has approved the complement C5 inhibitor avacincaptad pegol ( Izervay – Iveric) for intravitreal treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Avacincaptad pegol is the second complement inhibitor to be approved in the US for this indication; pegcetacoplan (Syfovre) , a complement C3 and C3b inhibitor, was approved earlier.
Issue 1675 · May 1, 2023
Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis

The FDA has approved Verkazia (Santen), a 0.1% ophthalmic emulsion formulation of the calcineurin inhibitor cyclosporine, for treatment of vernal keratoconjunctivitis (VKC). Verkazia is the first product to be…

Med Lett Drugs Ther. 2023 May 1; 65(1675):70-2 doi:10.58347/tml.2023.1675d
The FDA has approved Verkazia (Santen), a 0.1% ophthalmic emulsion formulation of the calcineurin inhibitor cyclosporine, for treatment of vernal keratoconjunctivitis (VKC). Verkazia is the first product to be approved in the US for this indication.
Issue 1673 · April 3, 2023
Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration

The FDA has approved the complement C3 inhibitor pegcetacoplan ( Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly…

Med Lett Drugs Ther. 2023 Apr 3; 65(1673):49-50 doi:10.58347/tml.2023.1673a
The FDA has approved the complement C3 inhibitor pegcetacoplan ( Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly or every-other-month (EOM) intravitreal injections, it is the first drug to become available for use in patients with atrophic dry AMD. Subcutaneous pegcetacoplan was approved earlier as Empaveli for treatment of paroxysmal nocturnal hemoglobinuria.
Issue 1672 · March 20, 2023
A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis

The FDA has approved Dextenza (Ocular Therapeutix), a dexamethasone ophthalmic insert, for treatment of ocular itching associated with allergic conjunctivitis. Dextenza was approved earlier for treatment of…

Med Lett Drugs Ther. 2023 Mar 20; 65(1672):45-6 doi:10.58347/tml.2023.1672b
The FDA has approved Dextenza (Ocular Therapeutix), a dexamethasone ophthalmic insert, for treatment of ocular itching associated with allergic conjunctivitis. Dextenza was approved earlier for treatment of ocular inflammation and pain following ophthalmic surgery.
Issue 1650 · May 16, 2022 Free
In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis

The ophthalmic H1-antihistamine alcaftadine 0.25%, which has been available by prescription since 2011 for use in patients with allergic conjunctivitis, is now available without a prescription as Lastacaft…

Med Lett Drugs Ther. 2022 May 16; 64(1650):78
The ophthalmic H1-antihistamine alcaftadine 0.25%, which has been available by prescription since 2011 for use in patients with allergic conjunctivitis, is now available without a prescription as Lastacaft Once Daily Relief (Allergan) for temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children ≥2 years old. It is the third ophthalmic antihistamine to be approved for over-the-counter (OTC) use (see Table 1).
Issue 1649 · May 2, 2022
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related…

Med Lett Drugs Ther. 2022 May 2; 64(1649):71-2
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor. Ranibizumab intravitreal injection (Lucentis) has been available since 2006 for monthly treatment of nAMD. The FDA has approved ranibizumab-nuna (Byooviz) , a biosimilar of Lucentis and the first ophthalmologic biosimilar; it will be available in June 2022.
Issue 1648 · April 18, 2022
A Drug-Eluting Contact Lens for Allergic Conjunctivitis

The FDA has approved Acuvue Theravision with Ketotifen (Johnson & Johnson Vision Care), a daily-wear, disposable, vision-correcting soft contact lens that releases the H 1 -antihistamine ketotifen, for…

Med Lett Drugs Ther. 2022 Apr 18; 64(1648):60-1
The FDA has approved Acuvue Theravision with Ketotifen (Johnson & Johnson Vision Care), a daily-wear, disposable, vision-correcting soft contact lens that releases the H 1 -antihistamine ketotifen, for prevention of ocular itch due to allergic conjunctivitis in contact lens users. This is the first approval for a drug-eluting contact lens. Ketotifen eye drops ( Alaway, Zaditor, and others) are available over the counter.
Issue 1646 · March 21, 2022
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

Faricimab-svoa ( Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet)…

Med Lett Drugs Ther. 2022 Mar 21; 64(1646):45-6
Faricimab-svoa ( Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Issue 1643 · February 7, 2022
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia

The FDA has approved Vuity (Abbvie), a 1.25% ophthalmic solution of the muscarinic receptor agonist pilocarpine hydrochloride, for treatment of presbyopia in adults. Pilocarpine 1%, 2%, and 4% ophthalmic…

Med Lett Drugs Ther. 2022 Feb 7; 64(1643):17-8
The FDA has approved Vuity (Abbvie), a 1.25% ophthalmic solution of the muscarinic receptor agonist pilocarpine hydrochloride, for treatment of presbyopia in adults. Pilocarpine 1%, 2%, and 4% ophthalmic solutions ( Isopto Carpine , and others) have been available for years for treatment of glaucoma, but local and systemic adverse effects have limited their use.
Issue 1625 · May 31, 2021
Teprotumumab (Tepezza) for Thyroid Eye Disease

Teprotumumab-trbw ( Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in…

Med Lett Drugs Ther. 2021 May 31; 63(1625):87-8
Teprotumumab-trbw ( Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in the US for this indication.
Issue 1622 · April 19, 2021
Drugs for Allergic Rhinitis and Allergic Conjunctivitis

The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1603 · July 27, 2020
Durysta - A Bimatoprost Implant for Glaucoma

The FDA has approved an intracameral implant containing the prostaglandin analog bimatoprost ( Durysta – Allergan) for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular…

Med Lett Drugs Ther. 2020 Jul 27; 62(1603):116-7
The FDA has approved an intracameral implant containing the prostaglandin analog bimatoprost ( Durysta – Allergan) for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bimatoprost is also available in 0.01% (Lumigan) and 0.03% (generics) ophthalmic solutions for the same indication and in a 0.03% solution (Latisse , and generics) for eyelash enhancement. Durysta is the first ocular implant to become available in the US for treatment of glaucoma.
Issue 1599 · June 1, 2020
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis

A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic…

Med Lett Drugs Ther. 2020 Jun 1; 62(1599):81-3
A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine ( Zyrtec , and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
Issue 1586 · December 2, 2019
Drugs for Common Eye Disorders

This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Dec 2; 61(1586):187-94
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Issue 1585 · November 18, 2019
Cannabis and Cannabinoids

Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of…

Med Lett Drugs Ther. 2019 Nov 18; 61(1585):179-82
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Issue 1558 · October 22, 2018
OTC Brimonidine (Lumify) for Ocular Redness

The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha 2 -adrenergic agonist brimonidine tartrate ( Lumify – Bausch & Lomb) for treatment of ocular redness in…

Med Lett Drugs Ther. 2018 Oct 22; 60(1558):176
The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha 2 -adrenergic agonist brimonidine tartrate ( Lumify – Bausch & Lomb) for treatment of ocular redness in adults and children ≥5 years old. Lumify is the first brimonidine product to be approved for OTC use.
Issue 1551 · July 16, 2018
Two New Drugs for Glaucoma

The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod ( Vyzulta – Bausch and Lomb), a…

Med Lett Drugs Ther. 2018 Jul 16; 60(1551):117-20
The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod ( Vyzulta – Bausch and Lomb), a modified prostaglandin analog, and netarsudil ( VRhopressa – Aerie), the first Rho kinase inhibitor to be approved in the US.
Issue 1543 · March 26, 2018
Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy

The FDA has approved voretigene neparvovec-rzyl intraocular suspension ( Luxturna – Spark), an adeno-associated virus vector-based gene therapy, for treatment of confirmed biallelic RPE65 mutation-associated…

Med Lett Drugs Ther. 2018 Mar 26; 60(1543):53-5
The FDA has approved voretigene neparvovec-rzyl intraocular suspension ( Luxturna – Spark), an adeno-associated virus vector-based gene therapy, for treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy in patients who have viable retinal cells. It is the first gene replacement therapy approved in the US that targets a disease caused by mutations in a specific gene and the first pharmacologic treatment to be approved for this disorder.
Issue 1523 · June 19, 2017
Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus

The FDA has approved the ophthalmic solutions riboflavin 5'-phosphate in 20% dextran ( Photrexa Viscous – Avedro) and riboflavin 5'-phosphate alone (Photrexa) for use with ultraviolet A (UVA) light (KXL…

Med Lett Drugs Ther. 2017 Jun 19; 59(1523):103-4
The FDA has approved the ophthalmic solutions riboflavin 5'-phosphate in 20% dextran ( Photrexa Viscous – Avedro) and riboflavin 5'-phosphate alone (Photrexa) for use with ultraviolet A (UVA) light (KXL System) in the corneal collagen cross-linking treatment of two corneal disorders: progressive keratoconus and corneal ectasia following refractive surgery. It is the first corneal collagen cross-linking (CXL) treatment to be approved by the FDA.
Issue 1502 · August 29, 2016
Lifitegrast (Xiidra) for Dry Eye Disease

The FDA has approved a 5% ophthalmic solution of lifitegrast ( Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye disease.…

Med Lett Drugs Ther. 2016 Aug 29; 58(1502):110-1
The FDA has approved a 5% ophthalmic solution of lifitegrast ( Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye disease. Lifitegrast is the first LFA-1 antagonist to be approved for any indication in the US.
Issue 1365 · May 30, 2011
New Treatments for Keratoconus

Keratoconus is a fairly common, progressive, noninflammatory, corneal-thinning disorder in which the cornea has a conical shape. Rigid gas permeable (RGP) contact lenses or corneal transplantation are…

Med Lett Drugs Ther. 2011 May 30; 53(1365):43-4
Keratoconus is a fairly common, progressive, noninflammatory, corneal-thinning disorder in which the cornea has a conical shape. Rigid gas permeable (RGP) contact lenses or corneal transplantation are effective treatments, but intracorneal ring segments and collagen cross-linking procedures offer some new alternatives in the management of the disease.
Issue 1212 · July 4, 2005
Pegaptanib Sodium (Macugen) for Macular Degeneration

The FDA has approved pegaptanib sodium ( Macugen - Pfizer/Eyetech) as an intravitreous injection for treatment of all subtypes of neovascular (wet) age-related macular degeneration (AMD). The only other…

Med Lett Drugs Ther. 2005 Jul 4; 47(1212):55-6
The FDA has approved pegaptanib sodium ( Macugen - Pfizer/Eyetech) as an intravitreous injection for treatment of all subtypes of neovascular (wet) age-related macular degeneration (AMD). The only other approved treatment for this condition is photodynamic therapy with intravenous verteporfin (Visudyne) , which is recommended only for patients with one subtype (predominantly classic) of neovascular AMD.
Issue 1211 · June 20, 2005
Viagra and Loss of Vision

The FDA recently announced that it was investigating 38 reports of loss of vision in men who took sildenafil (Viagra) , which has been used to treat erectile dysfunction since 1998.

Med Lett Drugs Ther. 2005 Jun 20; 47(1211):49
The FDA recently announced that it was investigating 38 reports of loss of vision in men who took sildenafil (Viagra) , which has been used to treat erectile dysfunction since 1998.
Issue 1185 · June 21, 2004
Conductive Keratoplasty (CK) for Presbyopia

The ViewPoint CK System (Refractec) for conductive keratoplasty (CK), previously approved by the FDA as a device for treatment of hyperopia (farsightedness), was recently approved for treatment of presbyopia…

Med Lett Drugs Ther. 2004 Jun 21; 46(1185):49-50
The ViewPoint CK System (Refractec) for conductive keratoplasty (CK), previously approved by the FDA as a device for treatment of hyperopia (farsightedness), was recently approved for treatment of presbyopia (age-associated loss of ability to view near objects).
Issue 1068 · December 17, 1999
Corneal Surgery for Correction of Refractive Errors

All refractive corneal surgery reshapes the cornea to redirect light rays so that they focus on the retine....

Med Lett Drugs Ther. 1999 Dec 17; 41(1068):122-3
All refractive corneal surgery reshapes the cornea to redirect light rays so that they focus on the retine....
Issue 956 · September 1, 1995
A Topical Carbonic Anhydrase Inhibitor For Glaucoma

Dorzolamide hydrochloride ( Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for…

Med Lett Drugs Ther. 1995 Sep 1; 37(956):76-7
Dorzolamide hydrochloride ( Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Issue 907 · October 15, 1993
Corneal Surgery for Myopia

Readers have inquired about the effectiveness and safety of operations on the cornea to correct refractive errors and restore normal vision without glasses or contact lenses. Several different operations are…

Med Lett Drugs Ther. 1993 Oct 15; 35(907):95-6
Readers have inquired about the effectiveness and safety of operations on the cornea to correct refractive errors and restore normal vision without glasses or contact lenses. Several different operations are now being used for this purpose.
Issue 864 · February 21, 1992
Reading Machines For The Blind

Electronic reading machines that convert print into speech have become increasingly useful for blind, other visually impaired, or dyslexic patients. Some of these devices are available as components that can…

Med Lett Drugs Ther. 1992 Feb 21; 34(864):13-4
Electronic reading machines that convert print into speech have become increasingly useful for blind, other visually impaired, or dyslexic patients. Some of these devices are available as components that can be added to a personal computer.
Issue 828 · October 5, 1990
Metipranolol: A New Beta-blocker For Glaucoma

Metipranolol hydrocholride 0.3% ( OptiPranolol - Bausch & Lomb), a nonselective beta-adrenergic receptor blocking drug, was recently marketed of ophthalmic use to decrease intraolular pressure in ocular…

Med Lett Drugs Ther. 1990 Oct 5; 32(828):91-2
Metipranolol hydrocholride 0.3% ( OptiPranolol - Bausch & Lomb), a nonselective beta-adrenergic receptor blocking drug, was recently marketed of ophthalmic use to decrease intraolular pressure in ocular hypertension or chronic open-angle glaucoma. Beta-blockers available in the USA for treatment of glaucoma are listed in this article.
Issue 823 · July 27, 1990
Soft Contact Lenses

Soft contact lenses have been in use for more than 20 years. Since the last Medical Letter review (vol. 24, page 109, 1982), new products have been developed, and some problems have emerged.

Med Lett Drugs Ther. 1990 Jul 27; 32(823):69-70
Soft contact lenses have been in use for more than 20 years. Since the last Medical Letter review (vol. 24, page 109, 1982), new products have been developed, and some problems have emerged.